Derek Weycker

Publication Activity (10 Years)

Years Active: 2017-2024
Publications (10 Years): 25

Top Topics

Idiopathic Pulmonary Fibrosis

Clinical Practice

Respiratory Tract

Acute Heart Failure

Top Venues

Infectious diseases and therapy

Current medical research and opinion

ERJ open research

This page only lists publications with an associated author ORCID identifier.

Publications

Derek Weycker, Ahuva Averin, Linnea Houde, Kevin Ottino, Kimberly Shea, Reiko Sato, Bradford D Gessner, Kari Yacisin, Daniel Curcio, Elizabeth Begier, Mark Rozenbaum
Rates of Lower Respiratory Tract Illness in US Adults by Age and Comorbidity Profile. Infectious diseases and therapy 13 (1) (2024)
Michael Kreuter, Joyce S Lee, Argyrios Tzouvelekis, Justin M Oldham, Philip L Molyneaux, Derek Weycker, Mark Atwood, Katerina Samara, Klaus-Uwe Kirchgässler, Toby M Maher
Modified blood cell GAP model as a prognostic biomarker in idiopathic pulmonary fibrosis. ERJ open research 10 (4) (2024)
Derek Weycker, Ahuva Averin, Linnea Houde, Kevin Ottino, Kimberly Shea, Reiko Sato, Bradford D Gessner, Kari Yacisin, Daniel Curcio, Elizabeth Begier, Mark Rozenbaum
Rates of Lower Respiratory Tract Illness in US Adults by Age and Comorbidity Profile. Infectious diseases and therapy (2024)
Derek Weycker, Ahuva Averin, Linnea Houde, Kevin Ottino, Kimberly Shea, Reiko Sato, Bradford D Gessner, Kari Yacisin, Daniel Curcio, Elizabeth Begier, Mark Rozenbaum
Rates of Lower Respiratory Tract Illness in US Adults by Age and Comorbidity Profile. Infectious diseases and therapy 13 (1) (2024)
Michael Kreuter, Joyce S Lee, Argyrios Tzouvelekis, Justin M Oldham, Philip L Molyneaux, Derek Weycker, Mark Atwood, Katerina Samara, Klaus-Uwe Kirchgässler, Toby M Maher
Modified blood cell GAP model as a prognostic biomarker in idiopathic pulmonary fibrosis. ERJ open research 10 (4) (2024)
Derek Weycker, Ahuva Averin, Linnea Houde, Kevin Ottino, Kimberly Shea, Reiko Sato, Bradford D Gessner, Kari Yacisin, Daniel Curcio, Elizabeth Begier, Mark Rozenbaum
Rates of Lower Respiratory Tract Illness in US Adults by Age and Comorbidity Profile. Infectious diseases and therapy 13 (1) (2024)
Derek Weycker, Ahuva Averin, Linnea Houde, Kevin Ottino, Kimberly Shea, Reiko Sato, Bradford D Gessner, Kari Yacisin, Daniel Curcio, Elizabeth Begier, Mark Rozenbaum
Rates of Lower Respiratory Tract Illness in US Adults by Age and Comorbidity Profile. Infectious diseases and therapy 13 (1) (2024)
Nirmish Shah, Thokozeni Lipato, Ofelia Alvarez, Thomas Delea, Alexander Lonshteyn, Derek Weycker, Andy Nguyen, Anne Beaubrun, Irene Agodoa
Real-world effectiveness of voxelotor for treating sickle cell disease in the US: a large claims data analysis. Expert review of hematology 15 (2) (2022)
Diana Mendes, Ahuva Averin, Mark Atwood, Reiko Sato, Andrew Vyse, James Campling, Derek Weycker, Mary P E Slack, Gillian F Ellsbury, Tendai Mugwagwa
Cost-effectiveness of using a 20-valent pneumococcal conjugate vaccine to directly protect adults in England at elevated risk of pneumococcal disease. Expert review of pharmacoeconomics & outcomes research 22 (8) (2022)
Tendai Mugwagwa, Ahuva Averin, Mark Atwood, Reiko Sato, Andrew Vyse, James Campling, Derek Weycker, Mary P E Slack, Gillian F Ellsbury, Diana Mendes
Public health and budgetary impact of 20-valent pneumococcal conjugate vaccine for adults in England. Expert review of vaccines 21 (9) (2022)
Frederic Douglas Seifer, Gary Hansen, Derek Weycker
Health-care utilization and expenditures among patients with comorbid bronchiectasis and chronic obstructive pulmonary disease in US clinical practice. Chronic respiratory disease 16 (2020)
Derek Weycker, Aaron Moynahan, Amanda Silvia, Reiko Sato
Attributable Cost of Adult Hospitalized Pneumonia Beyond the Acute Phase. PharmacoEconomics - open 5 (2) (2020)
Jordan Amdahl, Derek Weycker, Ray Farkouh, Liping Huang, Caitlin Eichten, Gerry Oster
Pediatric Vaccines and Cost-Effectiveness Thresholds: How Much is Too Much to Pay for Prevention? Infectious diseases and therapy 10 (1) (2020)
David H Henry, Derek Weycker, Mark Bensink, Prasad Gawade, Rajesh Belani
Optimal timing for pegfilgrastim administration in Japanese breast cancer patients receiving intermediate-risk chemotherapies: response to study by Hayama et al. International journal of clinical pharmacy 41 (3) (2019)
John Edelsberg, Derek Weycker, Mark E Bensink, Charles Bowers, Gary H Lyman
Prophylaxis of febrile neutropenia with colony-stimulating factors: the first 25 years. Current medical research and opinion 36 (3) (2019)
Michael Kreuter, David J Lederer, Vincent Cottin, Nicolas Kahn, Brett Ley, Carlo Vancheri, Derek Weycker, Mark Atwood, Klaus-Uwe Kirchgaessler, Christopher J Ryerson
Concomitant medications and clinical outcomes in idiopathic pulmonary fibrosis. The European respiratory journal 54 (6) (2019)
Derek Weycker, Mark Hatfield, Aaron Grossman, Ahuva Hanau, Alex Lonshteyn, Anjali Sharma, David Chandler
Risk and consequences of chemotherapy-induced thrombocytopenia in US clinical practice. BMC cancer 19 (1) (2019)
Derek Weycker, Ahuva Hanau, Mark Hatfield, Hongsheng Wu, Anjali Sharma, Mark E Bensink, David Chandler, Aaron Grossman, Michael Tarantino
Primary immune thrombocytopenia in US clinical practice: incidence and healthcare burden in first 12 months following diagnosis. Journal of medical economics 23 (2) (2019)
Derek Weycker, Robin Doroff, Ahuva Hanau, Charles Bowers, Rajesh Belani, David Chandler, Alexander Lonshteyn, Mark Bensink, Gary H Lyman
Use and effectiveness of pegfilgrastim prophylaxis in US clinical practice:a retrospective observational study. BMC cancer 19 (1) (2019)
Derek Weycker, Mark E Bensink, Alexander Lonshteyn, Robin Doroff, David Chandler
Use of colony-stimulating factor primary prophylaxis and incidence of febrile neutropenia from 2010 to 2016: a longitudinal assessment. Current medical research and opinion 35 (6) (2019)
Derek Weycker, Ahuva Hanau, Alexander Lonshteyn, Charles Bowers, Tamer Garawin, Mark E Bensink, David Chandler
Risk of chemotherapy-induced febrile neutropenia with early discontinuation of pegfilgrastim prophylaxis: a retrospective evaluation using Medicare claims. Current medical research and opinion 35 (4) (2018)
Derek Weycker, Ahuva Hanau, Alexander Lonshteyn, Charles Bowers, Mark E Bensink, Tamer Garawin, David Chandler
Risk of chemotherapy-induced febrile neutropenia with same-day versus next-day pegfilgrastim prophylaxis among patients aged ≥65 years: a retrospective evaluation using Medicare claims. Current medical research and opinion 34 (9) (2018)
Sophie Marbaix, Willy E Peetermans, Jan Verhaegen, Lieven Annemans, Reiko Sato, Annick Mignon, Mark Atwood, Derek Weycker
Cost-effectiveness of PCV13 vaccination in Belgian adults aged 65-84 years at elevated risk of pneumococcal infection. PloS one 13 (7) (2018)
John Edelsberg, Derek Weycker, Mark Atwood, Geoffrey Hamilton-Fairley, James R Jett
Cost-effectiveness of an autoantibody test (EarlyCDT-Lung) as an aid to early diagnosis of lung cancer in patients with incidentally detected pulmonary nodules. PloS one 13 (5) (2018)
Rebecca Bornheimer, Kimberly M Shea, Reiko Sato, Derek Weycker, Stephen I Pelton
Risk of exacerbation following pneumonia in adults with heart failure or chronic obstructive pulmonary disease. PloS one 12 (10) (2017)